Literature DB >> 16320102

Collapsing mechanistic models: an application to dose selection for proof of concept of a selective irreversible antagonist.

Matthew M Hutmacher1, Debu Mukherjee, Kenneth G Kowalski, David C Jordan.   

Abstract

When data fail to support fully mechanistic models, alternative modeling strategies must be pursued. Simpler, more empirical models or the fixing of various rate constants are necessary to avoid over-parameterization. Fitting empirical models can dilute information, limit interpretation, and cloud inference. Fixing rate constants requires external, relevant, and reliable information on the mechanism and can introduce subjectivity as well as complicate determining the validity of model extrapolation. Furthermore, both these methods ignore the possibility that failure of the data to support the mechanistic model could contain information about the pharmacodynamic process. If the pathway has processes with "fast" dynamics, these steps could collapse yielding parametrically simpler classes of models. The collapsed models would retain the mechanistic interpretation of the full model, which is crucial for performing substantive inference, while reducing the number of parameters to be estimated. These concepts are illustrated through their manifestations on the dose-effect relationship and ensuing dose selection for a proof of concept study. Specifically, a mechanistic model for a selective irreversible antagonist was posited and candidate classes of models were derived utilizing "fast dynamics" assumptions. Model assessment determined the rate-limiting step facilitating pertinent inference with respect to the mechanism. For comparison, inference using a more empirical modeling strategy is also presented. A general solution for the collapse of the typical PK-PD model differential equations is provided in Appendix A.

Mesh:

Substances:

Year:  2005        PMID: 16320102     DOI: 10.1007/s10928-005-0052-0

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  8 in total

1.  Time-dependent oral absorption models.

Authors:  K Higaki; S Yamashita; G L Amidon
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-04       Impact factor: 2.745

2.  Use of prior information to stabilize a population data analysis.

Authors:  Per O Gisleskog; Mats O Karlsson; Stuart L Beal
Journal:  J Pharmacokinet Pharmacodyn       Date:  2002-12       Impact factor: 2.745

3.  Characterization of four basic models of indirect pharmacodynamic responses.

Authors:  A Sharma; W J Jusko
Journal:  J Pharmacokinet Biopharm       Date:  1996-12

4.  A general conceptual model for non-steady state pharmacokinetic/pharmacodynamic data.

Authors:  D Verotta; L B Sheiner
Journal:  J Pharmacokinet Biopharm       Date:  1995-02

5.  Convergence of direct and indirect pharmacodynamic response models.

Authors:  W J Jusko; H C Ko; W F Ebling
Journal:  J Pharmacokinet Biopharm       Date:  1995-02

6.  Comparison of four basic models of indirect pharmacodynamic responses.

Authors:  N L Dayneka; V Garg; W J Jusko
Journal:  J Pharmacokinet Biopharm       Date:  1993-08

7.  Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check.

Authors:  Y Yano; S L Beal; L B Sheiner
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-04       Impact factor: 2.745

8.  A model for the turnover of dihydrotestosterone in the presence of the irreversible 5 alpha-reductase inhibitors GI198745 and finasteride.

Authors:  P O Gisleskog; D Hermann; M Hammarlund-Udenaes; M O Karlsson
Journal:  Clin Pharmacol Ther       Date:  1998-12       Impact factor: 6.875

  8 in total
  7 in total

1.  Fractional dynamics pharmacokinetics-pharmacodynamic models.

Authors:  Davide Verotta
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-05-09       Impact factor: 2.745

2.  Improvement in latent variable indirect response joint modeling of a continuous and a categorical clinical endpoint in rheumatoid arthritis.

Authors:  Chuanpu Hu; Honghui Zhou
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-11-09       Impact factor: 2.745

3.  Mechanism-based pharmacokinetic/pharmacodynamic modeling of rat prefrontal cortical dopamine response to dual acting norepinephrine reuptake inhibitor and 5-HT1A partial agonist.

Authors:  Cheryl Shuang-wu Li; Liming Zhang; Taraneh Haske; Amy Dounay; David Gray; Nancy Barta; Joanne Brodfuehrer; Christopher Lepsy; Brian Campbell
Journal:  AAPS J       Date:  2012-03-28       Impact factor: 4.009

Review 4.  Pharmacometrics: The Already-Present Future of Precision Pharmacology.

Authors:  Lorena Cera Bandeira; Leonardo Pinto; Cláudia Martins Carneiro
Journal:  Ther Innov Regul Sci       Date:  2022-08-18       Impact factor: 1.337

5.  Exposure-response modeling using latent variables for the efficacy of a JAK3 inhibitor administered to rheumatoid arthritis patients.

Authors:  Matthew M Hutmacher; Sriram Krishnaswami; Kenneth G Kowalski
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-12-06       Impact factor: 2.745

6.  Exposure-response modeling of clinical end points using latent variable indirect response models.

Authors:  C Hu
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2014-06-04

7.  Modelling the delay between pharmacokinetics and EEG effects of morphine in rats: binding kinetic versus effect compartment models.

Authors:  Wilhelmus E A de Witte; Vivi Rottschäfer; Meindert Danhof; Piet H van der Graaf; Lambertus A Peletier; Elizabeth C M de Lange
Journal:  J Pharmacokinet Pharmacodyn       Date:  2018-05-18       Impact factor: 2.745

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.